Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ibritumomab tiuxetan (IDEC-129) is an antibody targeting CD20, conjugated to a radioactive isotope via a chelating agent Tiuxetan, and can be used in radioimmunotherapy.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $195 | In Stock | |
5 mg | $483 | In Stock | |
10 mg | $692 | In Stock | |
25 mg | $1,080 | In Stock | |
50 mg | $1,490 | In Stock | |
100 mg | $1,970 | In Stock |
Description | Ibritumomab tiuxetan (IDEC-129) is an antibody targeting CD20, conjugated to a radioactive isotope via a chelating agent Tiuxetan, and can be used in radioimmunotherapy. |
In vitro | Ibritumomab tiuxetan is an anti-CD-20 mouse monoclonal antibody linked to the radioisotope 90-yttrium (90Y) by the chelating agent tiuxetan. [1] |
Alias | IDEC-129, IDEC129, BAY86-5128, BAY865128 |
Cas No. | 206181-63-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.